Sintilimab for endometrial neoplasms

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 6 Jan 2026: Trial registered, NCT07319429
  2. 25 Jan 2026: Trial started, NCT07319429

The trials

NCT07319429: Refining Fertility-sparing Treatment in Endometrial Carcinoma Based on Molecular Classification

State
Under way
Phase
Phase 2 and Phase 3
People
260 planned
Started
25 Jan 2026
Primary completion
31 Dec 2027
Arms
POLEmut Stage II Single-Arm Interventional Study
Results
None posted
  1. 6 Jan 2026: Trial registered
  2. 25 Jan 2026: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Also known as PD1 antibody, Sintilimab injection.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.